Detalhe da pesquisa
1.
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.
BMC Cancer
; 15: 713, 2015 Oct 16.
Artigo
Inglês
| MEDLINE | ID: mdl-26474549
2.
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.
Invest New Drugs
; 32(3): 436-44, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24258465
3.
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.
Invest New Drugs
; 32(6): 1204-12, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24919855
4.
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Ann Oncol
; 24(12): 3004-11, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24158411
5.
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Ann Oncol
; 24(3): 838-42, 2013 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-23139256
6.
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
Ann Oncol
; 24(8): 2158-65, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23576709
7.
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.
Ann Oncol
; 23(8): 1963-1967, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22377564
8.
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.
Ann Oncol
; 23(11): 2960-2963, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-22745218
9.
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
ESMO Open
; 7(6): 100639, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36493599
10.
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
ESMO Open
; 6(2): 100079, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33721621
11.
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.
Ann Oncol
; 20(6): 1080-5, 2009 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-19237479
12.
Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors.
Arch Dermatol Res
; 308(5): 357-65, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27098388
13.
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
Oncotarget
; 4(2): 310-5, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-23470635
14.
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Cancer Chemother Pharmacol
; 69(5): 1117-26, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22205203